Healio Coverage

November 21, 2020
1 min read

Top news from VIVA: Drug-coated devices, treatments for PAD and more


Healio Coverage

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Healio and Cardiology Today have aggregated the most-read news from the virtual VIVA 20.

Readers were most interested in the use of drug-coated devices and intravascular lithotripsy in peripheral artery disease, deep venous arterialization for severe CLI and more.

Breaking News
Source: Adobe Stock

Pooled analysis shows no 4-year mortality risk with low-dose PCB

In a pooled analysis of two randomized controlled trials of a low-dose paclitaxel-coated balloon to treat PAD, there was no mortality difference between the paclitaxel-coated balloon and an uncoated balloon at 4 years. Read more

DETOUR I: Percutaneous bypass system safe, effective at 24 months

A fully percutaneous bypass system using the femoral vein as a conduit was associated with high rates of patency and low rates of complications at 24 months in patients with severe PAD. Read more

Drug-coated devices associated with less unplanned limb revascularization: VOYAGER PAD

Among patients with PAD who had an endovascular procedure, treatment with a drug-coated device was linked to lower risk for unplanned limb revascularization, according to new data from the VOYAGER PAD trial. Read more

DCB remains effective in real-world PAD population at 5 years

In a real-world population of patients with PAD treated with a drug-coated balloon, nearly 70% remained free from clinically driven target lesion revascularization at 5 years, according to data presented at VIVA 20. Read more

Intravascular lithotripsy superior to PTA in patients with calcified PAD

In patients with calcified peripheral artery lesions treated with a drug-coated balloon, those who were pretreated with intravascular lithotripsy had better procedural outcomes than those pretreated with angioplasty, a speaker said at VIVA 20. Read more

Deep venous arterialization may benefit patients with severe CLI

In the single-arm PROMISE I study of deep venous arterialization in patients with severe critical limb ischemia, seven of 10 survived and were free from amputation at 1 year, according to data presented at the virtual VIVA 20. Read more

Bioabsorbable scaffold benefits high-risk patients with infrapopliteal disease

In a pooled analysis of three single-center studies, a bioresorbable scaffold was associated with high rates of patency and low rates of adverse events at 2 years in high-risk patients with infrapopliteal artery lesions. Read more